Viking Therapeutics stock: VK2735 improves BMI outcomes in trial
Published on 11/19/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSVK2735 advances through obesity trials
- Viking Therapeutics reported Phase 2 findings linking VK2735 treatment with improvements in BMI categories and cardiometabolic markers.
- The VANQUISH Phase 3 program is testing weekly injections in adults with obesity, including patients with type 2 diabetes.
- Viking expects the VANQUISH studies to be completed in 2027.
On November 15, Viking Therapeutics announced new clinical findings from its VK2735 obesity program at ObesityWeek 2026. The PR Newswire release said 74 percent of participants receiving weekly subcutaneous VK2735 improved by at least one BMI category after 13 weeks, compared with 15 percent receiving placebo.
Clinical findings broaden the case
The exploratory Phase 2 VENTURE analysis covered 124 participants. Those who improved by at least one BMI category also recorded larger reductions in waist circumference, fasting insulin and glucose, blood pressure, total cholesterol, triglycerides and LDL cholesterol than participants whose BMI category did not change.
Viking said earlier VENTURE results showed mean body-weight reductions of up to 14.7 percent after 13 weeks. Up to 88 percent of participants receiving VK2735 achieved at least 10 percent weight loss, compared with 4 percent for placebo. The company described 92 percent of drug-related treatment-emergent adverse events as mild or moderate.
Phase 3 program sets the next milestone
VK2735 is being evaluated in the VANQUISH-1 and VANQUISH-2 Phase 3 studies as a once-weekly subcutaneous injection. The trials are randomized, double-blind and placebo-controlled, with treatment planned for 78 weeks. VANQUISH-2 includes adults with overweight or obesity and type 2 diabetes.
Viking expects the VANQUISH studies to be completed in 2027. The company is also developing VK2735 in an oral formulation, keeping both injectable and oral approaches in its obesity pipeline.
Viking Therapeutics stock traded at 24.10 euros on Lang & Schwarz at 13:29 CET on Thursday, November 19, 2026.
Viking Therapeutics stock
- Company: Viking Therapeutics, Inc.
- ISIN: US92686J1060
- Ticker: VKTX
- Home exchange: Nasdaq
- Latest quote: 24.10 euros on Lang & Schwarz, November 19, 2026, 13:29 CET
- Business: Clinical-stage biopharmaceutical company
The broader U.S. market context is covered through the Nasdaq Composite.
